Dilution Information
Rabbit anti-Human ARID1A/BAF250a Monoclonal Antibody | anti-ARID1A antibody
ARID1A/BAF250a (EP303)
Reactivity
Human
Synonyms
ARID1A/BAF250a; Monoclonal Antibody; ARID1A/BAF250a (EP303); arid1a; anti-arid1a; arid; anti-arid; anti ARID1A; anti-BAF250A; anti BAF250A; ARID domain containing protein 1A; AT rich interactive domain 1A SWI like; AT rich interactive domain containing protein 1A; B120; BAF250; BM029; brain protein 120; BRG1 associated factor 250; BRG1 associated factor 250a; C1orf4; chromatin remodeling factor p250; hELD; hOSA1; Osa homolog 1; OSA1 nuclear protein; P270; SMARCF1; SWI like protein; SWI SNF complex protein p270; ELD; MRD14; OSA1; anti-ARID1A antibody
Host
Rabbit
Reactivity
Human
Clonality
Monoclonal
Isotype
IgG
Clone Number
EP303
Form/Format
Paraffin, Frozen
ARID1A is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
ARID1A is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
Immunogen
A synthetic peptide corresponding to residues of human ARID1A (BAF250a) protein.
Control
Breast, Fallopian Tube, Prostate, Testis, Transitional Cell Caricinoma, T Cell Lymphoblastic Lymphoma
Localization
Nuclear
Preparation and Storage
Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)
Dilution Information
Dilution Information
Immunohistochemistry (IHC)
(ARID1A Antibody Immunohistochemistry on an FFPE Ovarian Serous Carcinoma Tissue)
Immunohistochemistry (IHC)
(ARID1A Antibody Immunohistochemistry on an FFPE Ovarian Serous Carcinoma Tissue)
Related Product Information for anti-ARID1A antibody
Genes encoding subunits of SWItch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexes are collectively mutated in 20% of all human cancers. ARID1A is the SWI/SNF subunit gene that is most frequently mutated, at variable frequencies across molecular and histological subtypes of cancer.
ARID1A is a tumour suppressor gene frequently mutated in Clear Cell and Endometrioid Carcinomas of the Ovary and Endometrium. Loss of ARID1A function as shown by loss of expression, presumably due to mutations, is an early molecular event, occurring before malignant transformation, in the development of the majority of Ovarian Clear Cell and Endometrioid Carcinomas arising in Endometriomas. A study found 21 ARID1A antibody mutations were identified in 14/43 assessable tumours (33%), the majority of which were predicted to be deleterious. Mutations were identified in 6/17 (35%) Ovarian Clear Cell Carcinomas, 5/8 (63%) Ovarian Endometrioid Carcinomas, 2/5 (40%) Endometrial Carcinomas, and 1/7 (14%) Carcinosarcomas. Some studies have demonstrated that ARID1A has a critical tumor suppressor role in the Colon, and that its inactivation leads to the development of Colon Cancers via a mechanism that is distinct from previously established genetic models. ARID1A inactivating mutations are present at a high frequency in advanced endocrine-resistant ER+ Breast Cancer. ARID1A may play an important role in and serves as a valuable prognostic marker in Gastric Cancer.
ARID1A is a tumour suppressor gene frequently mutated in Clear Cell and Endometrioid Carcinomas of the Ovary and Endometrium. Loss of ARID1A function as shown by loss of expression, presumably due to mutations, is an early molecular event, occurring before malignant transformation, in the development of the majority of Ovarian Clear Cell and Endometrioid Carcinomas arising in Endometriomas. A study found 21 ARID1A antibody mutations were identified in 14/43 assessable tumours (33%), the majority of which were predicted to be deleterious. Mutations were identified in 6/17 (35%) Ovarian Clear Cell Carcinomas, 5/8 (63%) Ovarian Endometrioid Carcinomas, 2/5 (40%) Endometrial Carcinomas, and 1/7 (14%) Carcinosarcomas. Some studies have demonstrated that ARID1A has a critical tumor suppressor role in the Colon, and that its inactivation leads to the development of Colon Cancers via a mechanism that is distinct from previously established genetic models. ARID1A inactivating mutations are present at a high frequency in advanced endocrine-resistant ER+ Breast Cancer. ARID1A may play an important role in and serves as a valuable prognostic marker in Gastric Cancer.
Similar Products
Product Notes
The ARID1A (Catalog #AAA370515) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The ARID1A/BAF250a (EP303) reacts with Human and may cross-react with other species as described in the data sheet. It is sometimes possible for the material contained within the vial of "ARID1A/BAF250a, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
